Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY
Price:
$14
Market Cap:
$703.28B
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2021-01-08
Stock Exchange
PNK
Ticker
TAIPY
PE Ratio
[93.33]
ROE
[1.26%]
Current Ratio
[5.16]
Dividend Yield
[0.58%]
Enterprise Value
[466.10B]
Dividend History
The PE Ratio as of December 2024 (TTM) for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) is 93.33
According to Taisho Pharmaceutical Holdings Co., Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 93.33. This represents a change of 444.70% compared to the average of 17.13 of the last 4 quarters.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Historical PE Ratio (quarterly & annually)
How has TAIPY PE Ratio performed in the past?
The mean historical PE Ratio of Taisho Pharmaceutical Holdings Co., Ltd. over the last ten years is 27.96. The current 93.33 PE Ratio has changed 33.29% with respect to the historical average. Over the past ten years (40 quarters), TAIPY's PE Ratio was at its highest in in the June 2021 quarter at 100.70. The PE Ratio was at its lowest in in the March 2021 quarter at -155.03.
Average
27.96
Median
26.33
Minimum
17.66
Maximum
42.80
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Taisho Pharmaceutical Holdings Co., Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 62.90%
Maximum Annual PE Ratio = 42.80
Minimum Annual Increase = -33.06%
Minimum Annual PE Ratio = 17.66
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | 23.82 | -32.43% |
| 2022 | 35.25 | -17.63% |
| 2021 | 42.80 | 62.90% |
| 2020 | 26.27 | 48.79% |
| 2019 | 17.66 | -33.06% |
| 2018 | 26.38 | 5.10% |
| 2017 | 25.10 | -21.85% |
| 2016 | 32.12 | 8.69% |
| 2015 | 29.55 | 43.36% |
| 2014 | 20.61 | 4.59% |
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Average PE Ratio
How has TAIPY PE Ratio performed in the past?
The current PE Ratio of Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
33.96
5-year avg
29.16
10-year avg
27.96
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) PE Ratio vs. Peers
How is TAIPY’s PE Ratio compared to its peers?
Taisho Pharmaceutical Holdings Co., Ltd.’s PE Ratio is greater than Shionogi & Co., Ltd. (12.04), greater than Vivesto AB (-0.37), greater than Acorda Therapeutics, Inc. (-0.00), greater than Pacira BioSciences, Inc. (-9.90), less than Haleon plc (0), greater than Dr. Reddy's Laboratories Limited (32.26), greater than Emergent BioSolutions Inc. (21.13), greater than HUTCHMED (China) Limited (-2.11), greater than Viatris Inc. (-59.10), greater than Teva Pharmaceutical Industries Limited (-16.75), greater than Elanco Animal Health Incorporated (-25.61), greater than Catalent, Inc. (28.65), greater than Mallinckrodt plc (-27.97), greater than null (-0.04),
| Company | PE Ratio | Market cap |
|---|---|---|
| 12.04 | $12.05B | |
| -0.37 | $13.26M | |
| -0.00 | $821.03K | |
| -9.90 | $898.99M | |
| 0 | $44.09B | |
| 32.26 | $13.05B | |
| 21.13 | $449.73M | |
| -2.11 | $2.49B | |
| -59.10 | $14.80B | |
| -16.75 | $25.44B | |
| -25.61 | $5.87B | |
| 28.65 | $11.52B | |
| -27.97 | $4.52M | |
| -0.04 | $0 |
Build a custom stock screener for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taisho Pharmaceutical Holdings Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Taisho Pharmaceutical Holdings Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Taisho Pharmaceutical Holdings Co., Ltd.'s PE Ratio?
How is the PE Ratio calculated for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)?
What is the highest PE Ratio for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)?
What is the 3-year average PE Ratio for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)?
What is the 5-year average PE Ratio for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)?
How does the current PE Ratio for Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) compare to its historical average?